

CHAPTER IV APPENDIX

ATTACHMENT 1. Title Page/Outer Cover Lamp. 1a

ANALISIS BIAYA DAN VARIABEL YANG BERPENGARUH
TERHADAP BIAYA PENGOBATAN PASIEN GAGAL JANTUNG RAWAT INAP
DI RSUD SLEMAN YOGYAKARTA PERIODE TAHUN 2009

Usulan Penelitian Untuk Tesis S-2

Magister Manajemen Farmasi



Diajukan Oleh:

HERLIN SULITA

08/279476/PFA/00784

Kepada
PROGRAM PASCASARJANA
PROGRAM STUDI ILMU FARMASI
FAKULTAS FARMASI
UNIVERSITAS GADJAH MADA
YOGYAKARTA
Mei 2010

**ANALISIS BIAYA DAN VARIABEL YANG BERPENGARUH
TERHADAP BIAYA PENGOBATAN PASIEN GAGAL JANTUNG RAWAT INAP
DI RSUD SLEMAN YOGYAKARTA PERIODE TAHUN 2009**

TESIS
Untuk memenuhi sebagian persyaratan
mencapai derajat *Master of Science* (M.Sc.)

Magister Manajemen Farmasi



Diajukan Oleh:

HERLIN SULITA
08/279476/PFA/00784

Kepada
PROGRAM PASCASARJANA
PROGRAM STUDI ILMU FARMASI
FAKULTAS FARMASI
UNIVERSITAS GADJAH MADA
YOGYAKARTA
2011

**PENGARUH FAKTOR PEMBELAJARAN DAN PERTUMBUHAN
TERHADAP PROSES BISNIS INTERNAL: STUDI PADA INSTALASI
FARMASI RUMAH SAKIT DI DAERAH ISTIMEWA YOGYAKARTA
DAN JAWA TENGAH**

DISERTASI

Untuk memenuhi sebagian persyaratan
mencapai derajat Doktor (Dr.)



Diajukan Oleh:

SATIBI

07/259572/SMU/307

Kepada
PROGRAM PASCASARJANA
PROGRAM STUDI ILMU FARMASI
FAKULTAS FARMASI
UNIVERSITAS GADJAH MADA
YOGYAKARTA
2011

ANNEX 2: Approval PageLamp. 2a

Persetujuan Tesis Berjudul

.....
.....JUDUL TESIS.....
.....
.....

Oleh :

.....**nama mahasiswa**.....

.....NIM.....

untuk dipertahankan dihadapan panitia penguji tesis

Program Pascasarjana Program Studi Ilmu Farmasi

Fakultas Farmasi

Universitas Gadjah Mada

Yogyakarta

Pembimbing Utama

Pembimbing Pendamping

.....

.....

Tanggal :

Tanggal :

Persetujuan Disertasi Berjudul

.....
.....JUDUL DISERTASI.....
.....
.....

Oleh :

.....**nama mahasiswa**.....

.....NIM.....

untuk dipertahankan dihadapan panitia penguji komprehensif disertasi

Program Pascasarjana Program Studi Ilmu Farmasi

Fakultas Farmasi

Universitas Gadjah Mada

Yogyakarta

Promotor

Ko-promotor 1

.....

.....

Tanggal :

Tanggal :

Ko-promotor 2

.....

Tanggal :

Tesis	
.....JUDUL TESIS.....	
dipersiapkan dan disusun olehNAMA MAHASISWA....NIM....	
telah dipertahankan di depan Tim Penguji pada tanggal ...(diktetik tanggal ujian terbuka).....	
Pembimbing Utama 	Mengetahui: Fakultas Farmasi Universitas Gadjah Mada Dekan,
Pembimbing Pendamping 	Prof. Dr. Marchaban, DESS., Apt.
<u>Tim Penguji:</u>	
Ketua:nama penguji 1.....
Anggota:	
1.nama penguji 2.....	1.
2.nama pembimbing 1.....	2.
3.nama pembimbing 2.....	3.

DISERTASI

.....JUDUL DISERTASI.....
.....
.....
.....

dipersiapkan dan disusun oleh

...NAMA MAHASISWA...

...NIM....

telah dipertahankan di depan Tim Penguji pada tanggal(diketik tanggal ujian tertutup/terbuka).....

Promotor

.....
Ko Promotor I

.....
Ko Promotor II

Mengetahui:

Fakultas Farmasi
Universitas Gadjah Mada
Dekan,

Prof. Dr. Marchaban, DESS., Apt.

Tim Penquii:

Ketua:nama penguji 1.....

Anggota:

- | | |
|---------------------------------|---------|
| 1. nama pembimbing 1. | 1. |
| 2. nama pembimbing 2..... | 2. |
| 3. nama pembimbing 3..... | 3. |
| 4. nama penguji 2 | 4. |
| 5. nama penguji 3 | 5. |
| 6. nama penguji 4 | 6. |
| 7. nama penguji 5 | 7. |
| 8. nama penguji 6 | 8. |

APPENDIX 4. Statement Page

STATEMENT

I hereby declare that in this thesis/dissertation there is no work that has ever been submitted to obtain a graduate degree at a higher education institution, and to the best of my knowledge there is also no work or opinion that has ever been written or published by someone else, except for those that are referred to in writing in the text. this and is mentioned in the bibliography.

Yogyakarta, 8 June 2011

Student name

APPENDIX 5. Examples of writing titles, subtitles, sub-subtitles, sub-subtitles

CHAPTER II LITERATURE

REVIEW

A. Reproductive Neuroendocrine

Reproduction is a process that involves various functions at various levels. The reproductive system is highly dependent on *gonadotropin releasing hormone* (GnRH) which is produced and secreted by the brain. GnRH triggers the pituitary gland to produce and secrete gonadotropin hormones viz *luteinizing hormone* (LH) and *follicle stimulating hormone* (FSH).

B. GnRH and Regulation of GnRH Secretion

1. Self GnRH

a. Hypothalamus-pituitary-gonad (HPG) axis

GnRH is secreted in nerve endings in the outer zone of the median eminence (ME) and distributed to blood vessels

the portal pituitary, then acts on the gonadotrope cells in the pituitary gland (Fink, 1976).

i. Distribution of GnRH cells

In some animals, GnRH is found in *medial preoptic area* (MPOA) at the level of *vascular organ from terminal plate* (OVLT), as well as a few cells found in the cell nucleus in *arcuate* and the ventromedial part of the hypothalamus (VMN) (Lehman et al., 1986).

(a) GnRH cell mutation

Mutations that occur in the GnRH gene will cause hypogonadism which was first demonstrated in research using mice made hypogonadal (Cattanach et al., 1977). Deletion of exons III and IV of the GnRH gene will result in failure of mouse gonad development (Mason et al., 1986).

(b) GnRH cell lesion

Lesions in the cell nuclei *inarcuate* monkeys caused a decrease in both LH and FSH levels (Nakai et al., 1978).

b. Cellular GnRH and seasonal changes

Some animals in their reproductive activities are very dependent on long or short exposure to sunlight (*day length*) ... (Lincoln and Short, 1980).

2. Regulation of GnRH secretion

a. Nervous system

GnRH neurons are controlled by various nervous systems that both contain and do not contain estrogen receptor α ($ER\alpha$). GnRH cells in the cell nucleus *inarcuate*, in the VMN, in the BnST, in the POA as well as in the brainstem express $ER\alpha$, while GnRH cells in the lateral part of the hypothalamus do not contain $ER\alpha$ at all, but is believed to influence GnRH secretion through multi-synaptic pathways (Clarke and Tilbrook, 2009).

b. Steroid hormone feedback i. negative feedback

(a) Short-term feedback

(b) Long term feedback ii. positive feedback

APPENDIX 6. Examples of tables, figures and descriptions

Table 1. Lipid Profile in Serum of Rats Fed Normal and High Diet Fat On Day 45

Fat in serum (mg/dL)	D N	DT L	DTL+ G (36.5mg/kgB W)
Total cholesterol	80,5±2,6 _a	145,6±3,1	67,9±1,7 _a
Kolesterol LDL	108,4±3,4 _a	210,1±11,3	88,0±7,5 _a
Triglycerides	38,9±4,1 _a	67,5±3,4	22,3±1,8 _a

Information :

DN =diet normal

DTL = high fat diet

G = water extract *Kneeling down*(Lour.)Merr.

_a =significantly different from the DTL group (p <0.05)



Picture 1. Plants *Melastoma malabathricum* L.

APPENDIX 7. Examples of Punctuation Errors

Examples of punctuation

1. Semicolon

Semicolon (;) is used to separate sentences equivalent in a compound sentence as a substitute for a connecting word.

For example:

There are many uses for coconut, namely coconut meat can be made into cooking oil; Coconut fiber can be used to make rope, brush mats and rough rugs; the shell can be used as firewood or charcoal; The tree can be used as building material.

Actually, the details above can use commas, but it becomes difficult to see clearly the difference between the details of an equivalent compound sentence and the details of the elements in a smaller sentence. Another thing to note is that if a semicolon is used, before the final detail, there is no need to use the word **and**.

Apart from equivalent compound sentences, semicolons can also be used in downward details whose elements are long groups of words, or in the form of sentences. In this case, it is also necessary that no words be added to the final details **and**...

Compare the two uses below.

Incorrect form:

The emergence of new and old diseases is challenges in the field of health to make vaccines. Vaccine products are called ideal when the vaccine has the following criteria:

1. Efficient for all ages;
2. Can provide lifelong protection after 1 vaccination;
3. Easy to administer (better if given orally);
4. Does not produce unexpected effects (*adverse reaction*);
5. Stable under certain conditions;**and**
6. Available in unlimited quantities and cheap. Final punctuation in details **like above** can use a semicolon, but before the last detail **can't** use the word and.

Correct form:

The emergence of new and old diseases is challenges in the field of health to make vaccines. Vaccine products are called ideal when the vaccine has the following criteria:

1. Efficient for all ages;
2. Can provide lifelong protection after 1 vaccination;
3. Easy to administer (better if given orally);
4. Does not provide unexpected effects (*adverse reaction*);
5. Stable under certain conditions;
6. Available in unlimited quantities and cheap.

2. Colon (:)

Colons are often used out of place, especially in sentences containing details. This would not have happened if the authors had paid attention to the following rules.

- 1) The colon (:) is used in complete sentences followed by details in the form of words or phrases.

For example:

Water has the following properties:

- a. flowing from on high;
- b. always flat;
- c. according to the shape of the container.

The statement before the details is a complete sentence. If the sentence is complete, it will be followed by a detail in the form of words or phrases, then before the details need to be given a punctuation mark (:). In this case the colon has meaning *that is*. The details are written in lower case and end with a comma or semicolon. If you use commas, the details before the last word must be added **and** (like the example above).

2) A colon (:) is used before details which are complements or sentences. If the introductory sentence is incomplete, there is no need to include a colon.

For example:

The properties of water are

- Water has the following properties: a. flowing from a high place; b. always flat;
c. according to the shape of the container.

If there is a colon before the details, then the writing is not correct. For example, here is this.

The properties of water are:

- a. flowing from on high;
- b. always flat;
- c. according to the shape of the container.

3) The colon must be replaced with a period (.), in a complete sentence followed by details in the form of a complete sentence, and the end mark of the detail must be a period.

For example:

The properties of water are as follows:

- a. Water flows from high places.
- b. The water surface is always flat.
- c. The shape matches the shape of the container.

3. Return to the oven

1) Commas are used between elements in a detail or counting. For example:

I bought paper, pen and ruler.

Ordinary, express or special letters require postage.

2) A comma is used to separate one equivalent sentence from the next equivalent sentence which is preceded by the word like **but** or **but**

For example:

I want to come, but it's a rainy day.

Didi is not my child, but Mr. Kasim's child.

3) A comma is used to separate a sub-sentence from the main sentence if the sub-sentence precedes the main sentence

For example:

If it rains, I won't come. Because of busy, he forgot his promise

4) Commas are not used to separate a subordinate clause from the main sentence if the subordinate

clause accompanies the main sentence.

For example:

I won't come if it's a rainy day. He forgot his promise because he was busy

- 5) A comma is used after connecting words or expressions between sentences at the beginning of a sentence. These include therefore, so, moreover, even so and however.
- 6) Commas are also used to separate direct quotations from other parts of the sentence.

For example:

Sari (2010) stated, "Compound X, which is obtained from plant A, it turns out to be toxic to the kidneys"

APPENDIX 8. Example of bibliography

BIBLIOGRAPHY

- Astuti, P. and Gabrielli, B. 2011, Phosphorylation of Cdc25B3 Ser169 Regulates 14-3-3 Binding to Ser151 and Cdc25B Activity, *Cell Cycle*, **10**:1960-1967
- Bonate, P.T. and Howard, D.R. (eds) 2011, *Pharmacokinetics in Drug Development*, vol.3, *Advances and Applications*, Springer Verlaag, New York.
- Bourassa, S. 1999, 'Effects of Child Care on Young Children', *Proceedings of the Third Annual Meeting of the International Society for Child Psychology*, International Society for Child Psychology, Atlanta, Georgia, pp 44-6.
- Bowden, F.J. and Fairley, C.K. 1996, 'Endemic STDs in the Northern Territory: Estimations of Effective Rates of Partner Change', paper presented to the scientific meeting of the Royal Australian College of Physicians, Darwin, 24-25 June.
- Coleman, M.D. 2010, *Human Drug Metabolism, An Introduction*, 2nd edn, John Wiley and Sons, London. UK.
- Cutler, S.J. and Block, J.H. 2011, 'Metabolic Changes of Drugs and Related Organic Compounds', in Beale, JM and Block, JH, Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, 12th edn, Lippincott Williams and Wilkins, Philadelphia, pp 45-100.
- Daniel, T.T. 2009, 'Learning from Simpler Times', *Risk Management*, **56 (1)**: 40-44, accessed 30 January 2009, <<http://proquest.umi.com/>>
- Dennis, E.A. and Bradshaw, R.A. 2011, *Intercellular Signaling in Development and Disease*, Academic Press., San Diego, USA.
- Donahue-Wallace, K. and Chanda, J. 2005, 'A Case Study in Integrating the Best Practices of Face-to-face Art History and Online Teaching', *Interactive Multimedia Electronic Journal of Computer-Enhanced Learning*, **7(1)** accessed 30 January 2009, <<http://imej.wfu.edu/articles/2005/1/01/index.asp>>.
- Finn, O.J. 2008, Cancer Immunology, *New England Journal of Medicine*, **358**:2704-2715
- Gatra, 2011, Unraveling the Rare Meat Problem, *Gatra*, April 27, 2011, p. 45

- Golan , D.E. , Tashjian Jr. , A.H. , Armstrong , E.E. and Armstrong , A.W. 2012, *Principles of Pharmacology, the Pathophysiologic Basis of Drug Therapy*, 3rd ed., Lippincott Williams and Wilkins, Philadelphia.
- Hadi, S. 2011, 'Effect of Carbohydrate Fractions of Tomato Fruit (*Solanum lycopersicum*) in Inducing Macrophages to Synthesize Cell Killing Chemical Compounds *Whole Basically In vitro*', *Thesis*, MSc, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta.
- Huynh-Ba, K. (ed) 2010, *Pharmaceutical Stability Testing to Support Global Markets*, Springer. New York.
- Ministry of Health. 2008, *Regulation of the Minister of Health of the Republic of Indonesia, Number 10101 Menkes/Per/XI/2008, concerning Drug Registration*, Jakarta.
- Kristeva, J. 1995, *New Maladies of the Soul*, translated from German R Guberman, Columbia University Press, New York.
- Ma, Q., Zhou, B. and Pu, W.T. 2008, Reassessment of Isl1 and Nkx2-5 Cardiac Fate Maps using a Gata4-based Reporter of Cre Activity, *Developmental Biology*, **323**:98-104 cit. Epstein J.A., 2010, Cardiac Development and Implications for Heart Disease, *New England Journal of Medicine*, **363**:1638-47
- Martin , A. , Swarbrick , J. , Cammara , A. and Chun A.H.C. 1983, *Physical Pharmacy*, Translated by Yoshita, 1990, UI Press, Jakarta
- Ramsey, B.W., Davies, J., McElvaney, N., Tullis, E., Bell, S.C., Drevinek P. *et al.* 2011, A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation, *New England Journal of Medicine*, 365:1663-1672
- Sari, I.P., Rao, A., Smith, J.T., Tilbrook, A.J. and Clarke, I.J. 2009, Effect of RF-Amide-Related Peptide-3 on Luteinizing Hormone and Follicle-Stimulating Hormone Synthesis and Secretion in Ovine Pituitary Gonadotropes, *Endocrinology*, **150**:5549-5556
- Satibi. 2011, 'The Influence of Learning and Growth Factors on Internal Business Processes: Study on Hospital Pharmacy Installations in the Special Region of Yogyakarta and Central Java', *Dissertation*, Dr., Gadjah Mada University, Yogyakarta.
- Sorio, C. and Melotti, P. 2008, The Role of Macrophages and Their Scavenger Receptors in Cystic Fibrosis, *Journal of Leukocyte Biology*, **86**:465-468
- Van Hofe, E. 2011, A New Ally Against Cancer, *Scientific American*, October 2011, pp50-55
- Wainberg, M.A., Zaharatos, G.J. and Brenner, B.G. 2011, Development of Antiretroviral Drug Resistance, *New England Journal of Medicine*, **365**:637-646

World Health Organization. 2002, *WHO Expert Committee on Specifications for Pharmaceutical Preparations*, 36th Report, Singapore, WHO

Yuswanto, A., M., Atmaningsih, Kusumawan, A. 2010, Cytotoxic Effects of Ethanolic Extract of Red Betel (*Crispy pepper* Ruiz and Pav) against HeLa, SiHa, Myeloma, Raji and T47D cells, delivered at the XVIII Scientific Congress and National Working Meeting 2010 Indonesian Pharmacists Association, in Makasar, 10-12 December 2010

APPENDIX 9. Thesis Summary Title Page

RINGKASAN TESIS

EVALUASI PENGADAAN DAN KETERSEDIAAN OBAT
DI RSUD HADJI BOEJASIN PELAIHARI
TAHUN 2006-2008



Oleh:

Anna Apriyanti
08/277005/PFA/731

PROGRAM PASCASARJANA
PROGRAM STUDI ILMU FARMASI
FAKULTAS FARMASI
UNIVERSITAS GADJAH MADA
2011

(nomor hal.)

APPENDIX 10. Thesis Summary Approval Page

Persetujuan Ringkasan Tesis

.....JUDUL TESIS.....
.....
.....

Oleh :
.....nama mahasiswa (tanpa gelar).....
.....NIM.....

Telah disetujui oleh:

Pembimbing Utama

Pembimbing Pendamping

.....
Tanggal :

.....
Tanggal :

APPENDIX 11. Title Page *Summary*

SUMMARY

EVALUATION OF DRUG PROCUREMENT
AND AVAILABILITY AT HADJI BOEJASIN
GENERAL HOSPITAL OF PELAIHARI
2006-2008



Anna Apriyanti
08/277005/PFA/731

GRADUATE PROGRAM
FACULTY OF PHARMACY
UNIVERSITAS GADJAH MADA
2011

(nomor hal.)

APPENDIX 12. Page Approval of Thesis Summary

Approval of Thesis Summary

.....JUDUL TESIS DALAM BAHASA INGGRIS.....
.....
.....

.....nama mahasiswa (tanpa gelar).....
.....NIM.....

Approved by:

Primary Supervisor

Secondary Supervisor

.....
Date :

.....
Date :